




# WHO Global Malaria Programme

## Good procurement practices for artemisinin-based antimalarial medicines



World Health  
Organization





# Good procurement practices for artemisinin-based antimalarial medicines

## WHO Library Cataloguing-in-Publication Data

Good procurement practices for artemisinin-based antimalarial medicines.

1. Antimalarials – supply and distribution. 2. Artemisinins – supply and distribution.  
3. Antimalarials – standards. 4. Quality control. I. World Health Organization.

ISBN 978 92 4 159892 7 (NLM classification: QV 256)

### © World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Photos on cover: © WHO / Stephanie Hollyman (left photo) and © WHO / Silvia Schwarte (right photo).

Design and layout: Sue Hobbs, minimum graphics

# Contents

<b>Abbreviations</b>	<b>vi</b>
<b>Acknowledgements</b>	<b>vii</b>
<b>Glossary</b>	<b>viii</b>
<b>Purpose, target audience and objectives</b>	<b>xv</b>
<b>Introduction</b>	<b>1</b>
Why the quality of artemisinin-based antimalarial medicines is important	1
Challenges in ensuring the quality of artemisinin-based antimalarial medicines	1
Procurement checklist	4
<b>Step 1. Selecting safe, effective antimalarial medicines</b>	<b>7</b>
1.1 WHO guidelines	7
1.2 National guidelines	9
1.3 Special situations	9
1.4 Safe, effective antimalarial medicines and preferred presentations	9
<b>Step 2. Estimating requirements</b>	<b>12</b>
2.1 Quantification	12
2.2 Forecasting	13
<b>Step 3. Securing funding</b>	<b>14</b>
3.1 National funding	14
3.2 Donor funding	14
<b>Step 4. Defining product specifications</b>	<b>16</b>
<b>Step 5. Selecting the procurement method and preparing tender documents</b>	<b>24</b>
5.1 Procurement method	24
5.2 Tender documentation	24
<b>Step 6. Inviting tenders</b>	<b>26</b>
6.1 WHO Prequalification Programme	26
6.2 Stringent regulatory authorities	27
6.3 Risk assessment of products not approved by stringent authorities	29
6.4 Sources of quality-assured antimalarial finished pharmaceutical products	30
<b>Step 7. Investigating bid responses and validity</b>	<b>32</b>
7.1 Supplier criteria	32
7.2 Product criteria	32
<b>Step 8. Evaluating product quality</b>	<b>33</b>
8.1 Elements of product quality	33
8.2 Types of pharmaceutical product	34
8.3 Bioavailability and bioequivalence	35
8.4 Product stability	38
8.5 Pharmaceutical specifications and analytical methods	41

8.6	Control of active pharmaceutical ingredients.....	49
8.7	Good manufacturing practice.....	50
8.8	Packaging.....	51
8.9	Labelling.....	52
8.10	Product information and users.....	53
<b>Step 9.</b>	<b>Evaluating bids commercially.....</b>	<b>56</b>
9.1	Pricing information.....	56
9.2	Operational costs.....	57
9.3	Patents.....	57
<b>Step 10.</b>	<b>Contracts.....</b>	<b>59</b>
<b>Step 11.</b>	<b>Preshipment inspection and quality control.....</b>	<b>60</b>
11.1	Role of preshipment inspection and quality control.....	60
11.2	Contracting a laboratory.....	60
11.3	Shared arrangements.....	61
11.4	Preparation for sampling.....	61
11.5	Sampling for preshipment quality control.....	61
11.6	Interpretation of results.....	62
<b>Step 12.</b>	<b>Port clearance and receipt.....</b>	<b>63</b>
12.1	Before receipt of each shipment.....	63
12.2	On receipt of each shipment.....	63
12.3	After receipt of each shipment.....	64
<b>Step 13.</b>	<b>Postshipment quality control.....</b>	<b>65</b>
13.1	Extent of testing.....	65
13.2	Selection of laboratory.....	65
13.3	Interpretation of results.....	66
13.4	Reporting the results of quality control.....	66
<b>Step 14.</b>	<b>Storage and distribution.....</b>	<b>67</b>
14.1	Temperature monitoring and control.....	67
14.2	Stock control.....	67
14.3	Security and control of access.....	67
14.4	Batch traceability and recalls.....	67
<b>Step 15.</b>	<b>Monitoring supplier performance.....</b>	<b>68</b>
<b>Step 16.</b>	<b>Monitoring variations.....</b>	<b>69</b>
16.1	Detecting variations.....	69
16.2	Handling variations.....	70
<b>References</b>	<b>.....</b>	<b>72</b>
<b>Annexes</b>	<b>.....</b>	<b>77</b>
Annex 1.	WHO model certificate for a pharmaceutical product.....	78
Annex 2.	Stringent regulatory authorities.....	81
Annex 3.	Questionnaire on finished pharmaceutical products.....	82
Annex 4.	Elements of product quality, safety and efficacy.....	96
Annex 5.	Confirmed long-term stability testing conditions for countries.....	98
Annex 6.	WHO model certificate of good manufacturing practice.....	103
<b>Index</b>	<b>.....</b>	<b>105</b>

## Figures and tables

Figure 1. Levels of procurement of artemisinin-based antimalarial medicines.....	3
Table 1. WHO-recommended medicines for the treatment of malaria.....	8
Table 2. Preferred antimalarial product presentations (as of September 2009).....	10
Table 3. Model specification for a pharmaceutical product.....	16
Table 4. Quality-assured antimalarial finished pharmaceutical products (FPPs) .....	31
Table 5. Conditions for zone IV texting as per WHO guidelines.....	40
Table 6. Storage instructions as per WHO recommendations .....	40
Table 7. General pharmacopoeial requirements for dosage forms.....	45
Table 8. Requirements for analytical methods .....	46
Table 9. Information on use for prescribers and patients.....	54

# Abbreviations

ACT	artemisinin-based combination therapy
AL	artemether-lumefantrine
API	active pharmaceutical ingredient
AQ	amodiaquine
AS	artesunate
DHA	dihydroartemisinin
EMA	European Medicines Agency
FPP	finished pharmaceutical product
GFATM	Global Fund to Fight AIDS, Tuberculosis and Malaria
GMP	good manufacturing practice
ICH	International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
INN	International Nonproprietary Name
ISO	International Organization for Standardization
MQ	mefloquine
N.B.	nota bene (note well)
PPQ	piperaquine
SP	sulfadoxine-pyrimethamine
SRA	stringent regulatory authority
TRIPS	trade-related aspects of intellectual property rights (World Trade Organization)
UNFPA	United Nations Population Fund

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_29042](https://www.yunbaogao.cn/report/index/report?reportId=5_29042)

